Evidence map›Paper›PMID 42592061›Full record

ArticleActa pharmaceutica Sinica. B2026

CDK9 inhibition sensitizes intrinsically resistant

Ning Wei, Natalie Thielen, Mahshid Mohammadi, Muzaffer Ahmed Bhat, Terence Li, Yan Sun, Seiya Kitamura, Edward Chu, Chaoyuan Kuang

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ning WeiMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Natalie ThielenMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Mahshid MohammadiMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Muzaffer Ahmed BhatMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Terence LiMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Yan SunDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Seiya KitamuraMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Edward ChuMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Chaoyuan KuangMontefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
$726k
High Speed, High Resolution Slide Scanner for Research in Translational MedicineS10OD026852 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI CONDEELIS, JOHN S · 2022 to 2022
$472k
Cytek Aurora Multiparameter Flow CytometerS10OD026833 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI PORCELLI, STEVEN A · 2019 to 2019
$367k
NCI NIH HHS P30 CA013330NCI NIH HHS P30 CA016672NCI NIH HHS R50 CA221675NIH HHS S10 OD026833NIH HHS S10 OD026852
6 · The paper itself

Abstract

Recently, the BRAF inhibitor (Encorafenib) in combination with Cetuximab and mFOLFOX6 has been approved for the treatment of metastatic CRC (mCRC) patients with

Indexed as

BRAFCDK9Colorectal cancerDrug combinationDrug resistance

Identifiers

PMID42592061
PMCPMC13464074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.